From June 16 to 18, 2026, the 24th China International Exhibition of Pharmaceutical Ingredients and the 19th China International Exhibition of Pharmaceutical Machinery, Packaging Equipment and Materials (CPHI & PMEC China 2026) opened at the Shanghai New International Expo Centre. As a major annual event for the global pharmaceutical industry, the exhibition brought together more than 3,000 exhibitors from China and around the world, providing a comprehensive platform for exchange and collaboration across the pharmaceutical value chain, from R&D and manufacturing to supply.
HEAD Group made a prominent appearance in the international exhibition area at Booth E3D30, showcasing its flagship products, including Headcel pharmaceutical-grade cellulose ethers and the full range of Huili plant-based capsules. Through high-performance products, advanced technologies, and integrated solutions, HEAD Group demonstrated the innovation capabilities and international presence of a leading Chinese pharmaceutical excipient manufacturer.
At the exhibition, the HEAD Group booth attracted a steady stream of visitors, including domestic and international pharmaceutical manufacturers, industry partners, and customers across the value chain. The Group’s technical and sales teams were on site throughout the event, providing tailored support to address key customer needs, including product selection, formulation and process compatibility, regulatory submissions, and global supply chain coordination.
Through one-on-one technical consultations, customized product solutions, and end-to-end technical support, the team addressed diverse application requirements across pharmaceutical formulations, controlled-release technologies, film coating, and health and nutrition products. Building on years of participation in international exhibitions, HEAD Group engaged with both new and long-standing customers to exchange insights on industry trends, explore long-term strategic partnerships, and strengthen connections with markets in China and abroad. These interactions generated broad recognition and promising opportunities for future collaboration.
As a global manufacturer specializing in pharmaceutical-grade cellulose ethers and plant-based capsules, HEAD Group has established an integrated industrial system encompassing independent R&D, intelligent manufacturing, global supply, and technical services.
Its Headcel pharmaceutical-grade cellulose ether portfolio has completed the relevant review and approval procedures under China’s drug regulatory framework, with multiple standardized GMP-compliant production lines ensuring reliable supply. Its specialized products for controlled-release applications have also addressed technological gaps in the domestic market.
Huili Capsules, a wholly owned subsidiary of HEAD Group, leverages proprietary formulations and fully automated intelligent production lines to deliver a portfolio of plant-based hard capsules designed for safety, consistency, and broad formulation compatibility. Together, these two core business segments create complementary strengths and synergies across the value chain.
Supported by its global footprint, a stable and well-controlled supply chain, and continuously upgraded manufacturing capabilities, HEAD Group provides high-quality pharmaceutical excipient solutions to customers in the pharmaceutical and health industries worldwide, contributing to the pharmaceutical sector’s advancement toward greater standardization, higher value, and deeper international integration.
Looking ahead, HEAD Group will continue to invest in new product development and greener, smarter manufacturing, advancing technologies in pharmaceutical excipients and expanding its diverse, customized solutions to support innovation across the global pharmaceutical value chain.
At the same time, the Group will pursue an open and collaborative international growth strategy, further expanding its global market presence. Through reliable products, professional services, and the value of advanced Chinese manufacturing, HEAD Group aims to help bring pharmaceutical innovation to consumers worldwide and build a healthier future together.